6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone
Phase 3Recruiting 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small -Cell Lung
Conditions
Carcinoma, Non-Small -Cell Lung
Trial Timeline
Dec 8, 2025 โ Dec 31, 2027
NCT ID
NCT06908304About 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone is a phase 3 stage product being developed by MAIA Biotechnology for Carcinoma, Non-Small -Cell Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06908304. Target conditions include Carcinoma, Non-Small -Cell Lung.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06908304 | Phase 3 | Recruiting |
Competing Products
20 competing products in Carcinoma, Non-Small -Cell Lung